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We developed a fulminant colitis model in adolescent rats.
 The fulminant colitis model reproduces inﬂammatory bowel disease in humans.
 The rats were treated with hepatocyte growth factor, its activator, and arginine.
 The HGF treated rats had fewer days of pain.
 The arginine treated rats had fewer days of diarrhea.
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Introduction: Dextran sodium sulfate (DSS) is commonly used to induce a murine fulminant colitis
model. Hepatocyte growth factor (HGF) has been shown to decrease the symptoms of inﬂammatory
bowel disease (IBD) but the effect of its activator, HGFA, is not well characterized. Arginine reduces ef-
fects of oxidative stress but its effect on IBD is not well known. The primary aim is to determine whether
HGF and HGFA, or arginine will decrease IBD symptoms such as pain and diarrhea in a DSS-induced
fulminant colitis murine model.
Methods: A severe colitis was induced in young, male Fischer 344 rats with 4% (w/v) DSS oral solution for
seven days; rats were sacriﬁced on day 10. Rats were divided into ﬁve groups of 8 animals: control, HGF
(700 mcg/kg/dose), HGF and HGFA (10 mcg/dose), HGF and arginine, and high dose HGF (2800 mcg/kg/
dose). Main clinical outcomes were pain, diarrhea and weight loss. Blinded pathologists scored the
terminal ileum and distal colon.
Results: DSS reliably induced severe active colitis in 90% of animals (n ¼ 36/40). There were no differ-
ences in injury scores between control and treatment animals. HGF led to 1.38 fewer days in pain
(p ¼ 0.036), while arginine led to 1.88 fewer days of diarrhea (P ¼ 0.017) compared to controls. 88% of
HGFA-treated rats started regaining weight (P < 0.001).
Discussion/Conclusion: Although treatment was unable to reverse fulminant disease, HGF and arginine
were associated with decreased days of pain and diarrhea. These clinical interventions may reduce
associated symptoms for severe IBD patients, even when urgent surgical intervention remains the only
viable option.
© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The continuum of inﬂammatory bowel disease (IBD) includes
Crohn's disease (CD), Ulcerative Colitis (UC) and indeterminate
colitis. In adults and children alike, patients tend to present with
abdominal pain, diarrhea, rectal bleeding, weight loss, and perfo-
ration [1,2]. Children carry the additional burden of potential
growth retardation in moderate to severe UC [3].
Goals of management are to control or minimize disease by
suppressing inﬂammation and immune response modulation.
Despite this, approximately 15e30% of patients undergo subtotal
colectomy with end ileostomy due to disease progression, failure
of medical therapy or personal preference. Another 20e30% of
patients with fulminant colitis require urgent surgery [4e7].
Although the focus of medical therapy for UC has been on sup-
pression of inﬂammation, improved understanding is needed
about the potential effects of growth factors geared at the mucosa
in IBD.
Hepatocyte growth factor (HGF) is a heterodimer secreted by
mesenchymal cells found in the liver, lung, central nervous system
and the intestine and enhances epithelial cell proliferation in mu-
rine models [8]. HGF is known to decrease IBD symptomatology
and lowers intestinal injury scores in IBD rat models [9,10]. It has
additional beneﬁts of reducing inﬂammatory pathways and
apoptosis in liver injury [11] and ischemia-reperfusion models [12].
Conversely, the effect of its activator, hepatocyte growth factor
activator (HGFA), is not well delineated. Supplementing its acti-
vator should theoretically increase the effect of HGF and fulminant
colitis recovery. Finally, arginine (ARG) is an amino acid that has
protective effects against oxidative stress in healthy newborn rats,
hypoxia-reoxygenation, exercise and diabetes [13e15]. It likely
exerts effects via inducible nitric oxide synthase, which may in-
crease epithelial wound repair [16]. Consequently, it may protect
intestinal mucosa by ameliorating the inﬂammatory response seen
so commonly amongst IBD patients.
We hypothesized clinical and pathologic improvement in
colonic and terminal ileummucosa in an experimental rat model of
fulminant colitis versus control animals, by supplementing HGF
treatment with HGFA and arginine. We also expected that HGF plus
HGFA would synergistically promote earlier recovery from severe
acute colitis in the rodent model. Primary endpoints included
symptoms such as pain and diarrhea.
2. Materials and methods
2.1. Animal model
Following Institutional Animal Care and Use Committee
approval (local IACUC protocol 210084), an active, severe colitis was
induced in 40 young, male Fischer 344 rats (8e12 weeks of age)
with a 4% (w/v) DSS oral solution for seven days via standard water
bottles. The DSS solution was the water source for the animals
during the period of injury. 40 rats were divided equally into 5
groups by treatment regimen. Group 1 (control, n ¼ 8) was un-
treated and was a historical control; group 2 (HGF, n ¼ 8) received
700 mcg/kg/dose of HGF (Genentech, South San Francisco, CA)
subcutaneously on days 5, 7 and 9; group 3 (HGFþARG) was given
700 mcg/kg/dose of HGF and administered arginine as a 1% (w/v)
oral solution on days 5e10; group 4 (HGFþHGFA) was given
700 mcg/kg/dose of HGF and also given 10 mcg/dose of HGFA
(human recombinant HGF activator, R&D Systems, Minneapolis,
MN) subcutaneously on days 5 and 7; group 5 (HGFx4, high dose
HGF) was given 2800mcg/kg/dose of HGF. 700 mcg/kg/dose of HGF
was chosen tomirror the total HGF dose of a prior model [10]. HGFA
dosing was selected based on commercially available quantities,
since there is no published data for HGFA dosing. Treatment started
on day 5 based on our prior work that demonstrated the rats would
have an ongoing active colitis. All rats were sacriﬁced on day 10 to
allow for potential recovery after DSS injury ended on day 7. This
would allow for ﬁve total days of treatment and corresponds to
earlier surgical intervention, which is associated with improved
postoperative outcomes [17]. This timing also corresponds to the
point at which patients with steroid refractory UC should be
considered for colectomy (5e7 days) [18]. One animal in the argi-
nine group was sacriﬁced on day 9 due to signiﬁcant pain, weight
loss, lethargy and overall appearance.
2.2. Clinical monitoring
Rats were housed in standard polycarbonate individual caging
systems. They were allowed access to standard rat chow and water
ad libitum. On days 1e7, DSS was added to the water source in a 4%
concentration (w/v) [16]. Similarly for HGFþARG group, the water
source also included arginine (1% w/v) on days 5e10 [16].
A veterinarian and veterinarian technologists closely monitored
the rats. They were observed for overall health and their appear-
ance (hunched, not groomed), presence of diarrhea (Type 6 or 7 on
Bristol Stool Scale) [19] or gross blood, and need for pain medica-
tion was recorded. Rats were determined to be in pain if they
maintained a hunched position or a rufﬂed, unkempt coat [20] and
had binary documentation. If rats were deemed to be in pain on at
least one of the twice-daily checks they were marked as being in
pain for the day. Similarly, rats were marked as having diarrhea for
the day if a single stool was diarrhea. Buprenorphine (0.01 mg/
dose) was administered subcutaneously as necessary for pain
control.
2.3. Histopathology
Rats were euthanized with carbon dioxide at time of necropsy. A
midline laparotomy was used to harvest the similar segments of
distal colon and distal ileum. The specimens were stored in 10%
formalin, and delivered to two blinded pathologists. The small
bowel was graded on a scale from 0 to 8 (0 ¼ normal mucosa;
1 ¼ subepithelial space at villus tip; 2 ¼ extended subepithelial
space; 3 ¼ epithelial lifting along villus sides; 4 ¼ denuded villi;
5¼ loss of villus tissue; 6¼ crypt layer infarction; 7¼ transmucosal
infarction; 8 ¼ transmural infarction) [21]. The colon samples
(Fig. 1) were graded on a scale from 0 to 3 (0 ¼ no inﬂammation;
1 ¼ mild inﬂammation with cryptitis; 2 ¼ moderate inﬂammation
with crypt abscesses; 3¼ severe inﬂammationwith crypt abscesses
and surface erosion or ulceration) [10]. Injury scores were averaged
between the two pathologists.
2.4. Statistical analysis
Analysis of variance (ANOVA) with Bonferroni correction was
used to analyze the rats' appearance, pain, character of stool and
percent weight loss. Binary logistic regression was used to deter-
mine if rats started to regain weight. ANOVA with Bonferroni
correction was also used to analyze the rats' colon and small bowel
injury scores. Statistical signiﬁcance was set at P < 0.05.
2.5. Ethical considerations
Research on animals in this study was conducted in accordance
with the Guide for the Care and Use of Laboratory Animals published
by the National Research Council, 2010. This study was approved by
the local Institutional Review Board and the Institutional Animal
Care and Use Committee (IACUC) at the Madigan Army Medical
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Center. The facility where this research was conducted is fully
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. This work has been reported
in line with the ARRIVE statement [22].
3. Results
Overall, 38 of 40 (95%) animals reliably developed an acute co-
litis; 36 (90%) animals developed a severe active colitis. Treatment
with HGF, HGFA or arginine was unable to reverse this fulminant
disease. Colon injury scores (out of 3) for the various groups were as
follows: DSS ¼ 3.00; HGF ¼ 2.31; HGF þ HGFA ¼ 2.75;
HGFþARG¼ 3.00; HGFx4¼ 2.69. Small bowel injury scores (out of
8) were: DSS ¼ 2.63; HGF ¼ 2.00; HGF þ HGFA ¼ 3.00;
HGF þ ARG ¼ 2.25; HGFx4 ¼ 2.50. There was no difference in colon
or small bowel injury scores seen amongst treatment groups and
the DSS-injured control animals (Table 1; colon P ¼ 0.373; small
bowel P ¼ 0.545). All intervention groups had a signiﬁcantly higher
colon injury score than historical negative controls (Table 2). There
was no difference between the small bowel injury scores of the
DSS-injured animals and the treatment groups (Table 3).
Treatment groups spent 0.88e1.38 fewer days in pain as
compared to untreated control animals; however, only HGF-alone
animals reached statistical signiﬁcance with 1.38 less days of pain
(P ¼ 0.036, Table 4). Animals treated with HGF, high dose HGF and
arginine also experienced 0.38e1.88 fewer days of diarrhea and
hematochezia. Arginine supplementation was the only treatment
with a signiﬁcant difference with 1.88 fewer days of diarrhea
(P ¼ 0.017, Table 4). If it assumed that the one animal that was
sacriﬁced on day 9 would also have had diarrhea on day 10, argi-
nine supplementation still led to 1.75 fewer days of diarrhea
(P ¼ 0.028). There was no difference between groups with the
amount of painmedication administered.Meanpercent weight loss
varied from 10.35% for untreated animals to 15.44% for high dose
HGF treated animals (Table 4). Additionally, therewas no signiﬁcant
difference in the overall percent weight loss amongst groups.
However, 88% (7 out of 8) of HGFA-treated rats started to regain
weight by day 10 (P < 0.001, Fig. 2).
4. Discussion
Toxic or fulminant colitis in humans with IBD remain chal-
lenging from a medical management perspective. Accurate
modeling is essential for novel techniques. Our current rat model
reproduced severe and fulminant disease in 90% of rats. This reli-
able model was used to evaluate the impact of HGF, HGFA and
arginine.
Our results demonstrate low dose HGF is associated 1.38 fewer
days of pain and oral arginine supplementation is associated with a
signiﬁcant decrease in the number of days of diarrhea and hema-
tochezia. . Conversely, HGFA and high dose HGF were associated
with a non-signiﬁcant trend toward fewer days of pain with no
differences between high and low dose HGF. This reinforces the
concept of an HGF plateau point, after which increasing doses of
HGF no longer have an effect [10].
There were no signiﬁcant differences seen between treatment
groups in percentage of weight loss. This may be limited by the
duration of the study, since animals were only kept alive for 10 days
post-DSS injury. Nearly all HGFA-treated animals (7 of 8, 88%) had
Fig. 1. Hemotoxylin and eosin stained sections (40) of colon from dextran sodium sulfate (DSS)-induced colitis in rats.
Table 1
Average ileum and colon injury scores by treatment vs. injured control animals (DSS
alone).
Treatment Mean Std. error P value
Ileum (out of 8)
DSS alone 2.63 0.35 N/A
HGF 2.00 0.35 >0.999
HGFþHGFA 3.00 0.35 >0.999
HGFþARG 2.25 0.35 >0.999
HGFx4 2.50 0.35 >0.999
Colon (out of 3)
DSS alone 3.00 0.27 N/A
HGF 2.31 0.27 0.81
HGFþHGFA 2.75 0.27 >0.999
HGFþARG 3.00 0.27 >0.999
HGFx4 2.69 0.27 >0.999
Abbreviations: DSS ¼ dextran sodium sulfate; HGF ¼ hepatocyte growth factor;
HFGA ¼ hepatocyte growth factor activator; ARG ¼ arginine; HGFx4 ¼ high dose
hepatocyte growth factor.
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Table 2
Difference between average colon injury scores: DSS vs. treatment vs. normal.
(I) Treatment (J) Treatment Mean difference (IJ) Std. error P value 95% Conﬁdence interval
Lower bound Upper bound
DSS HGF 0.6875 0.36195 0.974 0.4443 1.8193
HGF þ ARG 0.0000 0.36195 >0.999 1.1318 1.1318
HGF þ HGFA 0.2500 0.36195 >0.999 0.8818 1.3818
HGFx4 0.3125 0.36195 >0.999 0.8193 1.4443
Normal 3.0000* 0.41269 <0.001 1.7096 4.2904
HGF DSS 0.6875 0.36195 0.974 1.8193 0.4443
HGF þ ARG 0.6875 0.36195 0.974 1.8193 0.4443
HGF þ HGFA 0.4375 0.36195 >0.999 1.5693 0.6943
HGFx4 0.3750 0.36195 >0.999 1.5068 0.7568
Normal 2.3125* 0.41269 <0.001 1.0221 3.6029
HGF þ ARG DSS 0.0000 0.36195 >0.999 1.1318 1.1318
HGF 0.6875 0.36195 0.974 0.4443 1.8193
HGF þ HGFA 0.2500 0.36195 >0.999 0.8818 1.3818
HGFx4 0.3125 0.36195 >0.999 0.8193 1.4443
Normal 3.0000* 0.41269 <0.001 1.7096 4.2904
HGF þ HGFA DSS 0.2500 0.36195 >0.999 1.3818 0.8818
HGF 0.4375 0.36195 >0.999 0.6943 1.5693
HGF þ ARG 0.2500 0.36195 >0.999 1.3818 0.8818
HGFx4 0.0625 0.36195 >0.999 1.0693 1.1943
Normal 2.7500* 0.41269 <0.001 1.4596 4.0404
HGFx4 DSS 0.3125 0.36195 >0.999 1.4443 0.8193
HGF 0.3750 0.36195 >0.999 0.7568 1.5068
HGF þ ARG 0.3125 0.36195 >0.999 1.4443 0.8193
HGF þ HGFA 0.0625 0.36195 >0.999 1.1943 1.0693
Normal 2.6875* 0.41269 <0.001 1.3971 3.9779
Normal DSS 3.0000* 0.41269 <0.001 4.2904 1.7096
HGF 2.3125* 0.41269 <0.001 3.6029 1.0221
HGF þ ARG 3.0000* 0.41269 <0.001 4.2904 1.7096
HGF þ HGFA 2.7500* 0.41269 <0.001 4.0404 1.4596
HGFx4 2.6875* 0.41269 <0.001 3.9779 1.3971
DSS ¼ dextran sodium sulfate; HGF ¼ hepatocyte growth factor; HFGA ¼ hepatocyte growth factor activator; ARG ¼ arginine; HGFx4 ¼ high dose hepatocyte growth factor.
Table 3
Difference between average small bowel injury scores: DSS vs. treatment vs. normal.
(I) Treatment (J) Treatment Mean difference (IJ) Std. error P value 95% Conﬁdence interval
Lower bound Upper bound
DSS HGF 0.313 0.377 >0.999 0.865 1.490
HGFþARG 0.188 0.377 >0.999 0.990 1.365
HGFþHGFA 0.188 0.377 >0.999 1.365 0.990
HGFx4 0.437 0.377 >0.999 0.740 1.615
Normal 2.750 0.429 <0.001 1.407 4.093
HGF DSS 0.313 0.377 >0.999 1.490 0.865
HGFþARG 0.125 0.377 >0.999 1.303 1.053
HGFþHGFA 0.500 0.377 >0.999 1.678 0.678
HGFx4 0.125 0.377 >0.999 1.053 1.303
Normal 2.437 0.429 <0.001 1.095 3.780
HGFþARG DSS 0.188 0.377 >0.999 1.365 0.990
HGF 0.125 0.377 >0.999 1.053 1.303
HGFþHGFA 0.375 0.377 >0.999 1.553 0.803
HGFx4 0.250 0.377 >0.999 0.928 1.428
Normal 2.562 0.429 <0.001 1.220 3.905
HGFþHGFA DSS 0.188 0.377 >0.999 0.990 1.365
HGF 0.500 0.377 >0.999 0.678 1.678
HGFþARG 0.375 0.377 >0.999 0.803 1.553
HGFx4 0.625 0.377 >0.999 0.553 1.803
Normal 2.937 0.429 <0.001 1.595 4.280
HGFx4 DSS 0.437 0.377 >0.999 1.615 0.740
HGF 0.125 0.377 >0.999 1.303 1.053
HGFþARG 0.250 0.377 >0.999 1.428 0.928
HGFþHGFA 0.625 0.377 >0.999 1.803 0.553
Normal 2.312 0.429 <0.001 0.970 3.655
Normal DSS 2.750 0.429 <0.001 4.093 1.407
HGF 2.437 0.429 <0.001 3.780 1.095
HGFþARG 2.562 0.429 <0.001 3.905 1.220
HGFþHGFA 2.937 0.429 <0.001 4.280 1.595
HGFx4 2.312 0.429 <0.001 3.655 0.970
DSS ¼ dextran sodium sulfate; HGF ¼ hepatocyte growth factor; HFGA ¼ hepatocyte growth factor activator; ARG ¼ arginine; HGFx4 ¼ high dose hepatocyte growth factor.
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started to regain weight by time of sacriﬁce (Fig. 2). This suggests
that HGFA can potentially reverse cachexia and malnutrition seen
in IBD, though a longer study period would is needed to fully
evaluate this.
Unfortunately, the treatments showed no pathologic differences
in colonic or small bowel samples. The majority of animals devel-
oped fulminant, unrecoverable disease over the course of the 5
treatment days. Although other groups have shown success with
HGF treatment in both HLA-B27 transgene and trinitrobenzene
sulfonic acid (TNBS) models, their animal models did not include
toxic disease [8,10]. This suggests that once IBD reaches toxic levels,
disease is irreversible with currently available medical manage-
ment modalities.
We acknowledge certain limitations to the present study. First,
optimal dosing of HGFA is unknown in the literature and HGFAwas
administered in its zymogen form. HGFA is activated in vivo in
response to tissue injury, likely by thrombin [23e25]; the DSS-
induced colitis would have created the necessary tissue injury to
activate HGFA. However, as a therapeutic agent, it may be more
effective to activate HGFA in vitro prior to infusion. Finally, HGFA
and arginine need to be compared as individual agents, instead of
as combined supplements to HGF therapy. Additionally, arginine
and DSS were administered as additives in drinking water. This
relies on each rat to self-administer the colitis-inducing agent and
the treatment, and does not ensure equal dosing. Lastly, intermit-
tent subcutaneous injections of HGF may have led to variable
concentrations, rather than continuous, therapeutic levels. Despite
these limitations, we have demonstrated that a fulminant colitis
model can be reliably created. We also reinforced that severe UC
and fulminant colitis represent signiﬁcant therapeutic challenges.
The goal is to initiate therapy quickly, but not persist with futile
treatment when surgery represents deﬁnitive care.
4.1. Conclusions
DSS can reliably create a signiﬁcant and severe colitis in rats,
Table 4
Days with diarrhea, days in pain and percent weight loss. Treatment groups versus control.
Treatment Days with diarrhea Days in Pain % Weight Loss
DSS alone Mean 4.13 1.87 10.35%
P value n/a n/a n/a
HGF Mean 3.38 0.50 12.94%
P value 0.321 *0.036 0.45
HGFþARG Mean 2.25 1.00 11.26%
P value *0.017 0.174 0.79
HGFþHGFA Mean 4.62 0.88 10.72%
P value 0.506 0.122 0.914
HGFx4 Mean 3.75 0.63 15.44%
P value 0.618 0.055 0.142
DSS ¼ dextran sodium sulfate; HGF ¼ hepatocyte growth factor; HFGA ¼ hepatocyte growth factor activator; ARG ¼ arginine; HGFx4 ¼ high dose hepatocyte growth factor.
Fig. 2. Average rat weight by day and treatment.
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replicating a human IBD model. Symptom improvement was
demonstrated in the HGF and arginine groups however these
treatments are unable to reverse fulminant disease. Therefore, HGA
and arginine may improve clinical symptoms in IBD patients until
an urgent/emergent operation is undertaken.
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